Skip to main content
Clinical Trials/NCT06450522
NCT06450522
Terminated
Not Applicable

Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF): a Randomized Controlled Trial

University of British Columbia1 site in 1 country12 target enrollmentJuly 4, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure with Reduced Ejection Fraction HFrEF
Sponsor
University of British Columbia
Enrollment
12
Locations
1
Primary Endpoint
Optimization Potential Score
Status
Terminated
Last Updated
last year

Overview

Brief Summary

This study will recruit 100 patients from a post-discharge medicine clinic to test if the addition of a pharmacist to manage heart failure medications can increase appropriate use of these medications. Participants will be randomly assigned to usual care alone or with the addition of a pharmacist to help manage medications. They will be followed for 3 months by telephone/electronically-administered questionnaires, and 12 months using administrative health records. Outcome data will include information from patients on quality of life, treatment burden, medication adherence, as well as information from their medical record on heart failure events.

Registry
clinicaltrials.gov
Start Date
July 4, 2024
End Date
February 21, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ricky Turgeon

Assistant Professor

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • Age ≥19 years;
  • Attending their initial visit to the PDMC;
  • Diagnosis of HF.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Optimization Potential Score

Time Frame: 3 months

Score that quantifies guideline-directed medical therapy (GDMT) use in heart failure with reduced ejection fraction. The score ranges from 0 (worst) to 10 (best). For HFmrEF, this will be modified to assign equal weight to ACEI/ARB/ARNI (score range 0-8). For HFpEF, this will be further modified to assign equal weight to ACEI/ARB/ARNI, and to assign no points for beta-blocker use (score range 0-6).

Secondary Outcomes

  • Composite hierarchical outcome(3 months)

Study Sites (1)

Loading locations...

Similar Trials